MARKET

ANVS

ANVS

Annovis Bio Inc
NYSE
0.7113
-0.0371
-4.96%
After Hours: 0.7188 +0.0075 +1.05% 19:38 11/20 EST
OPEN
0.7500
PREV CLOSE
0.7484
HIGH
0.7741
LOW
0.7000
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
0.6161
MARKET CAP
44.12M
P/E (TTM)
-0.4354
1D
5D
1M
3M
1Y
5Y
1D
Annovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA Agreement
NASDAQ · 2d ago
Annovis Bio secures FDA agreement on ISS plan for buntanetap NDA
TipRanks · 2d ago
Annovis Bio Receives FDA Approval Of Its Integrated Summary Of Safety Plan In Support Of Planned New Drug Application For Buntanetap
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Azora Therapeutics (AZR)
TipRanks · 5d ago
Annovis Bio receives second DSMB recommendation for DUET-AD trial
TipRanks · 5d ago
Annovis Bio Receives Second Consecutive Positive Recommendation From Independent Data And Safety Monitoring Board For Its DUET-AD Phase 3 Trial In Early Alzheimer's Disease; Six-Month Topline Results On Track For March 2027
Benzinga · 5d ago
Annovis Bio Price Target Cut to $3.00/Share From $7.00 by Roth Capital
Dow Jones · 6d ago
Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3
Benzinga · 6d ago
More
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Webull offers Annovis Bio Inc stock information, including NYSE: ANVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANVS stock methods without spending real money on the virtual paper trading platform.